Department of Ophthalmology, The Second Affiliated Hospital of Air Force Medical University, Xi'an, Shaanxi, 710038, China.
BMC Ophthalmol. 2024 Nov 26;24(1):510. doi: 10.1186/s12886-024-03779-x.
To highlight the safety and efficacy of tocilizumab (TCZ) in Graves' ophthalmopathy (GO) combined with ocular myasthenia gravis (OMG) patients refractory to steroids and cholinesterase inhibitor (CEI).
This was retrospective case series. We reviewed the health records of patients with GO combined with OMG, ten of whom were refractory to corticosteroids and CEI treatment and received intravenous injection of TCZ. Ten patients were treated with four injections of TCZ (intravenously, 8 mg per kilogram of body weight, once a month). We analyzed the efficacy and safety of TCZ treatment for this subset of patients with GO and OMG.
The main outcomes including quality of life questionnaire in Graves' orbitopathy (GO-QoL) score, Clinical Activity Score (CAS), Myasthenia Gravis Activities of Daily Living profile (MG-ADL) score, proptosis, diplopia and ptosis were assessed at 3 time points: "Baseline" (before the TCZ injection), "4th month" (after fourth time TCZ injection), "Follow up" (Last follow-up). Comparing parameters at 4th month vs. at baseline, all indicators improved at 4th month including GO-QoL score of visual functioning subscale (82.29 ± 13.71 vs. 35.98 ± 20.66, P < 0.001), GO-QoL score of the appearance subscale (80 ± 8.75 vs. 40.63 ± 17.95, P < 0.001), CAS (1.3 ± 0.46 vs. 4.5 ± 0.81, P < 0.001), MG-ADL (2.5 ± 1.56 vs. 5.11 ± 1.14, P < 0.001). Furthermore, proptosis decreased from 19.73 ± 2.84 to 17.93 ± 2.26 mm at 4th month (P < 0.0001). Diplopia and ptosis were also resolved at 4th month. After following up for a minimum of 11 months, the patients had no signs of relapse. In addition, we observed that all analyzed patients exhibited no significant drug reactions following the administration of TCZ.
Tocilizumab maybe a useful therapeutic option in refractory GO coexisting with OMG. However, considering the limitation of a retrospective study, short follow up period and small sample size of this study, randomized controlled studies are needed to validate our results.
强调托珠单抗(TCZ)在对类固醇和胆碱酯酶抑制剂(CEI)治疗反应不佳的 Graves 眼病(GO)合并眼肌型重症肌无力(OMG)患者中的安全性和疗效。
这是一项回顾性病例系列研究。我们回顾了合并 OMG 的 GO 患者的健康记录,其中 10 例对类固醇和 CEI 治疗反应不佳,接受 TCZ 静脉注射。10 例患者接受了 4 次 TCZ 治疗(静脉注射,每次 8mg/kg 体重,每月一次)。我们分析了 TCZ 治疗这组 GO 和 OMG 患者的疗效和安全性。
主要结局指标包括 Graves 眼病生活质量问卷(GO-QoL)评分、临床活动评分(CAS)、重症肌无力日常生活活动评分(MG-ADL)评分、突眼、复视和上睑下垂,在 3 个时间点进行评估:“基线”(TCZ 注射前)、“第 4 个月”(第 4 次 TCZ 注射后)、“随访”(末次随访)。与基线相比,第 4 个月的所有指标均有所改善,包括 GO-QoL 视觉功能子量表评分(82.29±13.71 对 35.98±20.66,P<0.001)、GO-QoL 外观子量表评分(80±8.75 对 40.63±17.95,P<0.001)、CAS(1.3±0.46 对 4.5±0.81,P<0.001)、MG-ADL(2.5±1.56 对 5.11±1.14,P<0.001)。此外,第 4 个月时突眼从 19.73±2.84 降至 17.93±2.26mm(P<0.0001)。复视和上睑下垂也在第 4 个月得到缓解。随访至少 11 个月后,患者均无复发迹象。此外,我们观察到所有接受 TCZ 治疗的患者均未出现明显药物不良反应。
托珠单抗可能是治疗对类固醇和胆碱酯酶抑制剂反应不佳的 GO 合并 OMG 的有效治疗选择。然而,鉴于回顾性研究的局限性、随访时间短和本研究的样本量小,需要进行随机对照研究来验证我们的结果。